Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Details Narrative)

v3.19.3
Stock-Based Compensation (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2019
Apr. 02, 2019
Mar. 15, 2019
Feb. 18, 2018
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Proceeds from issuance of common stock             $ 5,480,000
Stock-based compensation expense         $ 330,233 $ 324,473 1,177,282 899,649
Research and Development Expenses [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock-based compensation expense         61,374 $ 76,655 324,414 $ 198,475
Restricted Stock [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock-based compensation expense         $ 61,833   $ 144,278  
Employee Stock Purchase Plan [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of common stock reseved   250,000            
Vesting portion of stock   ESPP share purchase dates are March 31 and September 30, with an initial six month payroll deduction period of April 1, 2019 to September 30, 2019.            
Purchase price per share percentage on ESPP plan   85.00%            
Number of common stock issued 82,722              
Proceeds from issuance of common stock $ 67,436              
2014 Long Term Incentive Equity Plan [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of common stock reseved 7,951,081       7,951,081   7,951,081  
Shares of common stock available for grant of stock options 2,598,406       2,598,406   2,598,406  
Number of shares granted outside 500,854       500,854   500,854  
Number of options granted             1,875,000  
Exercise price per share             $ 1.00  
Contractual term of stock options             10 years  
Vesting period             36 months  
Number of stock options forfeited             48,611  
2014 Long Term Incentive Equity Plan [Member] | Restricted Stock [Member] | Employment Agreement [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Vesting portion of stock     Annual basis, commencing March 15, 2020 and ending March 15, 2022          
Number of restricted stock award granted     700,000          
Number of restricted stock award granted, value     $ 742,000          
2014 Long Term Incentive Equity Plan [Member] | Employees [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Weighted average fair value of stock options             $ 0.92 $ 1.22
2014 Long Term Incentive Equity Plan [Member] | Non-employees [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Weighted average fair value of stock options             $ 1.87 2.07
2018 Long Term Incentive Equity Plan [Member] | Lucid Diagnostics Inc [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of common stock reseved 2,000,000       2,000,000   2,000,000  
Shares of common stock available for grant of stock options 1,305,000       1,305,000   1,305,000  
Number of options granted             300,000  
Expected dividend yield             $ 0.00  
2018 Long Term Incentive Equity Plan [Member] | Employees [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Weighted average fair value of stock options         $ 0.32 $ 0.36 $ 0.40 $ 0.40
2018 Long Term Incentive Equity Plan [Member] | Non-employees [Member] | Lucid Diagnostics Inc [Member] | Research and Development Expenses [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock-based compensation expense         $ 3,247 $ 5,329 $ 11,552 $ 8,962
2018 Long Term Incentive Equity Plan [Member] | Employees and Non-employees [Member] | Lucid Diagnostics Inc [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Stock-based compensation expense         $ 8,720 $ 12,973 $ 141,778 $ 21,250
2018 Long-Term Incentive Equity Plan [Member] | Vesting Immediately [Member] | Lucid Diagnostics Inc [Member] | February 18, 2019 [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of options granted             620,000  
Vesting period             36 months  
Weighted average remaining contractual term of stock options outstanding             10 years  
2018 Long-Term Incentive Equity Plan [Member] | Employees [Member] | Vesting Immediately [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of options granted       200,000        
2018 Long-Term Incentive Equity Plan [Member] | Employees [Member] | Vesting on a Quarterly Basis [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Number of options granted       100,000        
Vesting period       35 months